In addition to contributing to CLL cell survival, CD40L has been implicated in drug resistance in CLL, with microenvironmental agonists including CD40L inducing NF-κB mediated resistance to Venetoclax and ibrutinib (88, 112, 113). The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.